DEXTER-CQA/TAT-QA-corpus huggingface dataset:
|||Income tax expense computed at federal statutory rate|State income taxes, net of federal tax benefit|Foreign income taxed at different rates|Settlements and reductions in uncertain tax positions|Tax credits|State valuation allowance, net of federal tax benefit|Equity-based compensation|Other permanent differences and miscellaneous items|U.S. tax reform impacts|
|June 30, 2019||$513,780|(17,565)|(260,344)|(31,291)|(71,779)|26,742|(7,566)|39,251|63,913|$255,141
Year Ended|June 24, 2018|(in thousands)|$891,011|(50,585)|(939,808)|(33,367)|(69,301)|57,302|(35,875)|43,214|908,517|$771,108
|June 25, 2017||$634,086|(11,973)|(352,860)|(144,519)|(37,713)|12,070|13,187|1,632|—|$113,910
Interest income decreased by $1.9 million from 2018 to 2019 due primarily to lower cash and marketable securities balances in 2019. Interest expense decreased by $8.2 million from 2018 to 2019 due primarily to unrealized losses on equity marketable securities recognized in 2018. Other (income) expense, net increased by $28.1 million from 2018 to 2019 due primarily to a $15.0 million charge for the impairment of the investment in RealWear and an $11.5 million change in pension actuarial (gains) losses from a $3.3 million gain in 2018 to an $8.2 million loss in 2019.
(In millions, except per share amounts)|Quarter Ended|Fiscal Year 2019|Revenue|Gross margin|Operating income|Net income (a)|Basic earnings per share|Diluted earnings per share (b)|Fiscal Year 2018|Revenue|Gross margin|Operating income|Net income (loss) (c)|Basic earnings (loss) per share|Diluted earnings (loss) per share (d)
|September 30||$  29,084|19,179|9,955|8,824|1.15|1.14||$  24,538|16,260|7,708|6,576|0.85|0.84
|December 31||$  32,471|20,048|10,258|8,420|1.09|1.08||$ 28,918|17,854|8,679|(6,302)|(0.82)|(0.82)
|March 31||$  30,571|20,401|10,341|8,809|1.15|1.14||$ 26,819|17,550|8,292|7,424|0.96|0.95
|June 30||$  33,717|23,305|12,405|13,187|1.72|1.71||$ 30,085|20,343|10,379|8,873|1.15|1.14
|Total||$  125,843|82,933|42,959|39,240|5.11|5.06||$ 110,360|72,007|35,058|16,571|2.15|2.13
||Numerator:|Consolidated net income|Denominator:|Denominator for basic earnings per common share—weighted-average common shares outstanding|Effect of dilutive stock options and awards under the treasury stock method|Denominator for diluted earnings per common share—weighted-average common shares outstanding plus dilutive common shares under the treasury stock method|Basic earnings per common share|Diluted earnings per common share
|2019||$1,503||767|4|771|$1.96|$1.95
For the Years Ended December 31,|2018||$1,848||762|9|771|$2.43|$2.40
|2017||$273||754|12|766|$0.36|$0.36
|||Cost of revenue|Research and development|Sales and marketing|General and administrative|Total
|2019||$2,843|6,532|9,069|10,693|$29,137
Year Ended December 31,|2018|(In thousands)|$2,435|4,283|8,267|11,476|$26,461
|2017||$1,406|2,968|5,481|9,114|$18,969
As of December 31, 2019, $7.8 million of unrecognized compensation cost related to stock options is expected to be recognized over a weighted-average period of 2.1 years and $41.3 million of unrecognized compensation cost related to unvested RSUs is expected to be recognized over a weighted-average period of 2.2 years. If there are any modifications or cancellations of the underlying unvested awards, the Company may be required to accelerate, increase or cancel all or a portion of the remaining unearned stock-based compensation expense.
|||Revenues|Cost of goods sold|Gross profit (loss)|Gross profit %|Selling, general and administrative expenses|Loss from operations|Other income (expense):|Interest expense|Other, net|Total other (expense) income|Loss before income taxes
Years Ended December 31|2019|(in thousands)|$23,713|24,574|(861)|-3.6%|13,696|(14,557)|(96)|50|868|822|$(13,735)
|2018||$14,762|11,780|2,982|20.2%|11,194|(8,212)|(12)|-|168|156|$(8,056)
Change|%||60.6|(108.6)|||(22.4)|(77.3)|||||
($ in millions)|At December 31, 2019:|Recorded investment:|Lease receivables|Loan receivables|Ending balance|Recorded investment, collectively evaluated for impairment|Recorded investment, individually evaluated for impairment|Allowance for credit losses|Beginning balance at January 1, 2019|Lease receivables|Loan receivables|Total|Write-offs|Recoveries|Provision|Other*|Ending balance at December 31, 2019|Lease receivables|Loan receivables|Related allowance, collectively evaluated for impairment|Related allowance, individually evaluated for impairment
|Americas||$ 3,419|6,726|$10,144|$10,032|$   112|||$    53|105|$   158|(42)|1|5|(1)|$   120|$    33|$    88|$    25|$    96
|EMEA||$1,186|3,901|$5,087|$5,040|$   47|||$   22|43|$   65|(3)|0|(7)|0|$   54|$   23|$   31|$   11|$   43
|Asia Pacific||$  963|2,395|$3,359|$3,326|$   32|||$   24|32|$   56|(18)|1|(3)|(1)|$   36|$   16|$   20|$    4|$   32
|Total||$ 5,567|13,022|$18,590|$18,399|$   191|||$     99|179|$   279|(63)|2|(5)|(2)|$   210|$    72|$   138|$    39|$   171
|||Selling, general and administrative expenses|Research and development expenses|Total operating expenses|As percentage of net revenues
|December 31, 2019||$(285)|(387)|$(672)|(24.4)%
Three Months Ended|September 29, 2019||$(267)|(362)|$(629)|(24.7)%
|December 31, 2018|(Unaudited, in millions)|$(285)|(345)|$(630)|(23.8)%
% Variation|Sequential||(6.3)%|(7.0)|(6.7)%|+30 bps
|Year-Over-Year||0.4%|(12.3)|(6.6)%|-60 bps
The Group leases various offices in locations such as Amsterdam, the Netherlands; the San Francisco Bay Area, California, New York, New York, Austin, Texas, and Boston, Massachusetts, United States; Sydney, Australia; Manila, the Philippines; Bengaluru, India; Yokohama, Japan; and Ankara, Turkey under non-cancellable operating leases expiring within one to nine years. The leases have varying terms, escalation clauses and renewal rights. On renewal, the terms of the leases are renegotiated. The Group incurred rent expense on its operating leases of $38.6 million, $23.6 million, and $12.2 million during the fiscal years ended 2019, 2018 and 2017, respectively.
||Fiscal Period:|Year ending 2020|Years ending 2021 - 2024|Thereafter|Total commitments
Operating Leases|||$38,790|148,021|144,037|$330,848
Other Contractual Commitments|(U.S. $ in thousands)||$108,978|219,342|—|$328,320
Total|||$147,768|367,363|144,037|659,168
|METRO|METRO Germany|METRO Western Europe (excl.Germany)|METRO Russia|METRO Eastern Europe (excl.Russia)|METRO Asia|Others|METROAG|Total
2018|86,239|11,816|24,073|13,884|28,264|8,202|6,916|863|94,018
2019|82,979|11,760|24,044|12,288|27,589|7,298|7,067|837|90,883
Selling, General and Administrative Costs (in thousands)|Description|Start-up expense (Tyler, Texas complex) |Legal services expense |All other SG&A |Administrative salary expense|Trainee expense |Charter aircraft expense|Depreciation expense - machinery and equipment |Stock compensation expense |Marketing expense|Start-up expense (St. Pauls, North Carolina complex) |Bonus award program expense |Employee Stock Ownership Plan ("ESOP") expense|Total SG&A 
|Twelve months ended October 31, 2018|$13,394|17,573|68,863|42,288|21,553|2,167|5,801|15,702|32,624|—|—|2,000|$221,965
|Twelve months ended October 31, 2017|$403|7,879|61,847|36,193|16,182|900|4,555|16,952|34,272|4,022|15,098|18,000|$216,303
|Increase/(Decrease) |$ 12,991|9,694|7,016|6,095|5,371|1,267|1,246|(1,250)|(1,648)|(4,022)|(15,098)|(16,000)|$ 5,662
||Stock-based compensation by type of award:|Stock options|Stock awards|Employee stock purchase rights(1)|Total|Stock-based compensation by category of expense:|Cost of revenue|Sales and marketing|Research and development|General and administrative|Total
|2019||$648|14,882|999|$16,529||$1,500|5,765|6,039|3,225|$16,529
Years Ended December 31,|2018||$1,353|10,445|5,240|$17,038||$1,602|5,667|6,631|3,138|$17,038
|2017||$2,705|11,421|3,077|$17,203||$1,362|6,075|6,343|3,423|$17,203
|Federal statutory income tax rate|Increase (decrease) resulting from:      |Foreign tax rate differences|Withholding tax on dividends |Permanent differences |Excess tax benefits related to share-based compensation |Global intangible low-taxed income ("GILTI") |Deemed repatriation tax |Non-deductible compensation|Valuation allowances |Rate changes |Other, net |Effective income tax rate
2019|21.0 %||(21.0)|(5.4)|(1.3)|(1.3)|11.7|5.6|1.5|1.5|—|1.5|13.8 % 
2018|24.5 % ||(30.2)|23.7|0.8|(2.7)|—|92.2|0.2|(30.6)|9.0|1.0|87.9 % 
2017|35.0 %||(39.9)|—|3.0|(2.0)|—|—|0.2|12.2|—|(0.5)|8.0 %
|||Selling, general and administrative|% of revenues||||Selling, general and administrative|% of revenues
|December 28, 2019||$106,335|18.0 %||December 29, 2018||$99,254|18.7 %
Fiscal Year Ended|December 29, 2018|(Dollars in thousands)|$99,254|18.7 %|Fiscal Year Ended|December 30, 2017|(Dollars in thousands)|$95,489|17.4 %
|$ Change||$7,081|||$ Change||$3,765|
|% Change||7.1 %|||% Change||3.9 %|
($ in millions)|Reporting Segment|Grocery & Snacks|Refrigerated & Frozen|International|Foodservice|Commercial|Total
|Fiscal 2018 Net Sales|$3,287.0|2,753.0|843.5|1,054.8|—|$7,938.3
|Fiscal 2017 Net Sales|$3,208.8|2,652.7|816.0|1,078.3|71.1|$7,826.9
|% Inc (Dec)|2%|4%|3%|(2)%|(100)%|1%
International net sales for fiscal 2018 were $843.5 million, an increase of $27.5 million, or 3%, compared to fiscal 2017. Results for fiscal 2018 reflected a 3% decrease in volume, a 3% increase due to foreign exchange rates, and a 3% increase in price/mix, in each case compared to fiscal 2017. The volume decrease for fiscal 2018 was driven by strategic decisions to eliminate lower margin products and to reduce promotional intensity. The increase in price/mix compared to the prior-year period was driven by improvements in pricing and trade productivity.
Refrigerated & Frozen net sales for fiscal 2018 were $2.75 billion, an increase of $100.3 million, or 4%, compared to fiscal 2017. Results for fiscal 2018 reflected a 3% increase in volume compared to fiscal 2017, excluding the impact of 31 acquisitions. The increase in sales volumes was a result of brand renovation and innovation launches. Price/mix was flat compared to fiscal 2017, as favorability in both net pricing and mix offset continued investment in retailer marketing to drive brand saliency, enhanced distribution, and consumer trial. The acquisition of the Sandwich Bros. of Wisconsin® business contributed $21.3 million to Refrigerated & Frozen's net sales during fiscal 2018. The Frontera acquisition, which occurred in September 2016, and subsequent innovation in the Frontera® brand contributed $4.4 million during fiscal 2018 through the one-year anniversary of the acquisition.
Grocery & Snacks net sales for fiscal 2018 were $3.29 billion, an increase of $78.2 million, or 2%, compared to fiscal 2017. Results reflected a decrease in volumes of approximately 2% in fiscal 2018 compared to the prior-year period, excluding the impact of acquisitions. The decrease in sales volumes reflected a reduction in promotional intensity, planned discontinuation of certain lower-performing products, retailer inventory reductions, which were higher than anticipated, and deliberate actions to optimize distribution on certain lower-margin products, consistent with the Company's value over volume strategy. Price/ mix was flat compared to the prior-year period as favorable mix improvements from recent innovation and higher net pricing nearly offset continued investments in retailer marketing to drive brand saliency, enhanced distribution, and consumer trial. The acquisition of Angie's Artisan Treats, LLC contributed $68.1 million to Grocery & Snacks net sales during fiscal 2018. The Frontera acquisition contributed $8.6 million and the Thanasi acquisition contributed $66.5 million to Grocery & Snacks net sales during fiscal 2018 through the one-year anniversaries of the acquisitions. The Frontera and Thanasi acquisitions occurred in September 2016 and April 2017, respectively.
Under U.S. GAAP, companies may make reasonable aggregations and approximations of returns data to accurately estimate returns. Our AirBar and sensor module returns and warranty experience to date has enabled us to make reasonable returns estimates, which are supported by the fact that our product sales involve homogenous transactions. The reserve for future sales returns is recorded as a reduction of our accounts receivable and revenue and was insignificant as of December 31, 2019 and 2018.
||Dividends paid during the year (net of dividend re-investment)|4 cent per share final dividend paid 27 September 2018 – fully franked1|3 cent per share final dividend paid 30 September 2017 – fully franked|3 cent per share interim dividend paid 29 March 2019 – fully franked|3 cent per share interim dividend paid 29 March 2018 – fully franked||Proposed dividend not recognised at the end of the year|Dividends franking account|30% franking credits, on a tax paid basis, are available to shareholders of Hansen Technologies Ltd for subsequent financial years
2019|$’000||7,319||5,318||12,637|5,922||1,586
2018|$’000|||5,175||5,217|10,392|7,865||3,125
|(Amounts in thousands)|Cost of sales:|Farm production|Processing and packaging|Outside egg purchases and other|Total shell eggs|Egg products|Other|Total|Farm production cost (per dozen produced)|Feed|Other|Total|Outside egg purchases (average cost per dozen)|Dozen produced|Dozen sold
Fiscal Year Ended|June 1, 2019||$ 635,797|222,765|249,605|1,108,167|29,020|1,142|$1,138,329||$0.415|0.319|$0.734|$1.26|876,705|1,038,900
|June 2, 2018||$ 603,887|214,078|287,472|1,105,437|35,551|898|$1,141,886||$0.394|0.303|$0.697|$1.45|873,307|1,037,713
|Percent Change||5.3 %|4.1%|(13.2)%|0.2 %|(18.4)%|27.2%|(0.3)%||5.3%|5.3%|5.3%|(13.1)%|0.4%|0.1%
Quarter Ended|June 1, 2019||$ 162,142|55,584|44,509|262,235|5,139|444|$267,818||$0.411|0.328|$0.739|$1.05|222,625|254,772
|June 2, 2018||$ 155,471|53,734|81,623|290,828|10,743|308|$301,879||$0.416|0.311|$0.727|$1.82|215,729|251,955
|Percent Change||4.3%|3.4%|(45.5)%|(9.8)%|(52.2)%|44.2%|(11.3)%||(1.2)%|5.5%|1.7%|(42.3)%|3.2%|1.1%
Cost of sales for the fiscal year ended June 1, 2019 was $1,138.3 million, a decrease of $3.6 million, or 0.3%, compared to $1,141.9 million for fiscal 2018. Comparing fiscal 2019 to fiscal 2018, average cost per dozen purchased from outside shell egg producers decreased while cost of feed ingredients and dozens produced increased. For the 2019 fiscal year we produced 84.4% of the eggs sold by us, as compared to 84.2% for the previous year. Feed cost for fiscal 2019 was $0.415 per dozen, compared to $0.394 per dozen for the prior fiscal year, an increase of 5.3%. The increase in feed costs was primarily related to less favorable crop conditions in the south central U. S., which resulted in higher ingredient prices at some of our larger feed mill operations. The increase in feed cost per dozen resulted in an increase in cost of sales of $18.4 million for fiscal 2019 compared with fiscal 2018.
For the thirteen weeks ended June 1, 2019, compared to the thirteen weeks ended June 2, 2018, cost of sales decreased $34.1 million, or 11.3%, from $301.9 million in the fourth quarter of fiscal 2018, to $267.8 million in the fourth quarter of fiscal 2019. Average cost per dozen purchased from outside shell egg producers decreased 42.3% due to significantly lower egg selling prices in the quarter. Feed cost per dozen for the fourth quarter of fiscal 2019 was $0.411, compared to $0.416 for the same quarter of fiscal 2018, a decrease of 1.2%.
|(In millions)|Accruals not yet deductible for tax purposes|Net operating loss carryforwards|Foreign, federal and state credits|Employee benefit items|Capitalized expenses|Intangibles|Derivatives and other|Sub-total deferred tax assets|Valuation allowance|Total deferred tax assets|Depreciation and amortization|Unremitted foreign earnings|Intangible assets|Other|Total deferred tax liabilities|Net deferred tax assets
December 31,|2019|$ 17.4|245.9|8.4|79.5|32.2|21.8|47.7|452.9|(197.6)|$ 255.3|$ (37.0)|(10.0)|—|(0.4)|(47.4)|$ 207.9
|2018|$ 17.5|265.5|10.4|77.0|8.9|—|38.0|417.3|(218.4)|$ 198.9|$ (26.8)|—|(21.7)|(0.4)|(48.9)|$ 150.0
Costs of warranty include the cost of labor and materials to repair a product during the warranty period. The main term of the warranty period is one year. The Company accrues for the estimated cost of the warranty on its products shipped in the provision for warranty, upon recognition of the sale of the product. The costs are estimated based on actual historical expenses incurred and on estimated future expenses related to current sales, and are updated periodically. Actual warranty costs are charged against the provision for warranty.
TELEPHONY Fiscal 2019 fourth-quarter telephony service customers net losses stood at 304 compared to net additions of 1,150 for the same period of the prior year mainly as a result of a decline in the residential sector, partly offset by growth in the business sector. TELEPHONY Fiscal 2019 fourth-quarter telephony service customers net losses stood at 304 compared to net additions of 1,150 for the same period of the prior year mainly as a result of a decline in the residential sector, partly offset by growth in the business sector.
|||Gross profit|Gross margin (as percentage of net revenues)
|December 31, 2019||$ 1,081|39.3%
Three Months Ended|September 29, 2018|(Unaudited, in millions)|$ 967|37.9%
|December 31, 2018||$ 1,059|40.0%
Variation|Sequential||11.8%|+140 bps
|Year-Over-Year||2.0%|-70 bps
At December 31, 2019, approximately $96 million of total unrecognized compensation cost was related to RSUs and is expected to be recognized over a weighted-average period of 1.64 years. Of the total unrecognized compensation cost, $50 million was related to performance-based RSUs, which is expected to be recognized over a weighted-average period of 1.63 years. The total grant date fair value of vested RSUs was $147 million, $120 million and $64 million for the years ended December 31, 2019, 2018, and 2017, respectively.
||Expected life (in years)|Volatility|Risk-free interest rate|Dividend yield
|2019|0.5|36% - 37%|1.58 - 2.43%|- %
Year ended December 31|2018|0.5|33% - 40%|1.76% - 2.50%|- %
|2017|0.5|29% - 37%|0.76% - 1.16%|- %
The Company issued 266 shares, 231 shares and 183 shares under the ESPP in the years ended December 31, 2019, 2018 and 2017, respectively, at a weighted average
exercise price per share of $86.51, $77.02, and $73.02, respectively. As of December 31, 2019, the Company expects to recognize $3,531 of the total unamortized compensation cost
related to employee purchases under the ESPP over a weighted average period of 0.37 years.
|Lease obligations and facility exit costs (1)|Severance and related costs (2)|Severance and related costs (1)|Non-cash impairment charges|Other non-cash charges|
Americas 2018 Exit Plan|$7,073|3,426|1,037|5,875|—|$17,411
Americas 2019 Exit Plan|$—|191|2,155|1,582|244|$4,172
Garo H. Armen, PhD, Executive Chairman, is one of our founders and joined us in September 2004. Garo H. Armen is Chairman and Chief Executive Officer of Agenus
Inc., a biotechnology company he co-founded in 1994. From mid-2002 through 2004, he also served as Chairman of the Board of the biopharmaceutical company Elan
Corporation, plc, which he successfully restructured. Prior to Agenus Inc., Dr. Armen established Armen Partners, a money management firm specializing in biotechnology and
pharmaceutical companies and was the architect of the widely publicized creation of the Immunex Lederle oncology business in 1993. Earlier, he was a senior vice president of
research at Dean Witter Reynolds, having begun his career on Wall Street as an analyst and investment banker at EF Hutton. In 2002, Dr. Armen founded the Children of
Armenia Fund, a nonprofit organization dedicated to significantly rebuilding and revitalizing impoverished rural Armenian towns to provide immediate and sustainable benefits
to children and youth. He received the Ellis Island Medal of Honor in 2004 for his humanitarian efforts, and received the Sabin Humanitarian Award from the Sabin Vaccine
Institute in 2006 for his achievements in biotechnology and progressing medical research. Dr. Armen was also the Ernst & Young 2002 New York City Biotechnology
Entrepreneur of the Year, and received a Wings of Hope Award in 2005 from The Melanoma Research Foundation for his ongoing commitment to the melanoma community. Dr.
Armen received a PhD in physical chemistry from the Graduate Center, City University of New York, after which he worked as a research fellow at Brookhaven National
Laboratories in Long Island, NY. Dr. Armen brings to our Board a deep historical and practical knowledge of the business of the Company and its technologies, as well as
years of expertise in the financial and biopharmaceutical arenas.
||Reconciliation to consolidated net revenues:|Segment net revenues|Revenues from non-reportable segments (1)|Net effect from recognition (deferral) of deferred net revenues (2)|Elimination of intersegment revenues (3)|Consolidated net revenues|Reconciliation to consolidated income before income tax expense:|Segment operating income|Operating income (loss) from non-reportable segments (1)|Net effect from recognition (deferral) of deferred net revenues and related cost of revenues (2)|Share-based compensation expense|Amortization of intangible assets|Restructuring and related costs (4)|Discrete tax-related items (5)|Consolidated operating income|Interest and other expense (income), net|Loss on extinguishment of debt|Consolidated income before income tax expense
For the Years Ended December 31,|2019||$5,969|462|101|(43)|$6,489||$2,054|24|52|(166)|(203)|(137)|(17)|1,607|(26)|—|$1,633
|2018||$6,835|480|238|(53)|$7,500||$2,446|31|100|(209)|(370)|(10)|—|1,988|71|40|$1,877
||Net revenues by distribution channel:|Digital online channels (1)|Retail channels|Other (2)|Total consolidated net revenues
|2019||$4,932|909|648|$6,489
For the Years Ended December 31,|2018||$5,786|1,107|607|$7,500
|Increase/ (decrease)||$(854)|(198)|41|$(1,011)
|% Change||(15)%|(18)|7|(13)
||||Balance, beginning of the year||Other comprehensive income (loss) before reclassifications|Loss on cash flow hedges reclassified from accumulated other comprehensive income (loss) to earnings were as follows:|Cost of revenues|Sales and marketing|Research and development|General and administrative|Tax effect on unrealized gain (loss) on cash flow hedges|Other comprehensive income (loss), net of tax|Balance, end of the year
Accumulated Other Comprehensive Income (Loss)|Years ended|December 31, 2019|$|(12,216)||12,865||279|1,538|2,620|744|(4,784)|13,262|1,046
||December 31, 2018|$|3,435||(19,821)||255|1,224|2,063|628|—|(15,651)|(12,216)
1. 2019 Performance Periods and Performance Goals. For the calendar year 2019, there are four quarterly Performance Periods, ending on March 31, June 30, September 30 and December 31, 2019 (each, a “2019 Performance Period”). For each of the four 2019 Performance Periods, there are two equally weighted (50% each) performance goals (each, a “2019 Performance Goal”): Revenue and Operating Margin (each as defined below). The chart below set forth the Revenue and Operating Margin Performance Goals for the four 2019 Performance Periods.
|||Net income - Insurance segment|Effect of investment (gains) (1)|Asset impairment expense|Gain on bargain purchase|Gain on reinsurance recaptures|Acquisition costs|Insurance AOI|Income tax expense (benefit)|Pre-tax Insurance AOI
||2019|$59.4|(1.9)|47.3|(1.1)|—|2.1|105.8|(20.1)|$85.7
Year ended December 31,||2018|$165.2|(5.6)|—|(115.4)|(47.0)|2.8|—|0.6|$0.6
|Increase /|(Decrease)|$(105.8)|3.7|47.3|114.3|47.0|(0.7)|105.8|(20.7)|$85.1
|||Assets|Cash and cash equivalents|Marketable securities|Derivative assets|Liabilities|Contingent consideration|Derivative liabilities|Convertible debt (1)
December 31, 2019|Carrying Value|||$773,924|241,793|528||39,705|203|394,687
|Fair Value|(in thousands)||$773,924|241,793|528||39,705|203|1,010,275
December 31, 2018|Carrying Value|||$926,752|277,827|79||70,543|514|379,981
|Fair Value|||$926,752|277,827|79||70,543|514|547,113
|Weighted average common shares—basic|Dilutive effect of stock options|Dilutive effect of restricted stock|
Year Ended December 31, 2019|45,542,315|32,222|505,858|46,080,395
Year Ended December 31, 2018|45,280,161|33,134|467,659|45,780,954
Year Ended December 31, 2017|44,855,263|31,534|297,406|45,184,203